The US Food and Drug Administration has approved Skinvive by Juvéderm for the treatment of neck lines and neck appearance, extending the product's cleared use into a new anatomical region.

The clearance, reported by The Dermatology Digest, adds a neck-focused indication to the Skinvive label. The published source item does not specify the FDA action date, the exact wording of the approved use statement, or the clinical data underpinning the decision.

What does the new indication cover?

The approval covers neck lines and what the source labels as neck "appearance." Aesthetic practitioners regularly treat neck concerns alongside facial work because patients raise both in a single consultation. Neck lines and skin quality are common drivers of consult volume for practices offering injectable rejuvenation.

The headline does not clarify whether the cleared indication targets fine horizontal neck lines, vertical platysmal bands, skin texture changes, or a broader skin-quality endpoint. Until the FDA-approved labeling is published, injectors should treat the announcement as preliminary and refrain from rewriting their protocols around the new use.

What does the ruling change for clinics?

For practices already offering Skinvive, the neck clearance reshapes consult flow. Patients who previously had to be referred out, treated off-label, or steered toward alternative products can now be assessed for an in-portfolio option. That changes the chairside conversation and the pricing menu.

Operations teams should expect:

• Updated marketing collateral and in-office imagery from the manufacturer
• Revised consent forms referencing the neck indication
• Internal training updates once physician education modules are issued
• Compliance documentation tracking the labeling revision

Procurement does not need new SKUs; the same Skinvive product is now cleared for an additional anatomical area under revised labeling.

What details are still pending?

Industry-standard data points were absent from the source item. Watch for:

• The FDA action date and approval letter docket
• The full indication statement in the revised prescribing information
• Pivotal trial design, enrollment size, and primary efficacy endpoint
• Duration of effect and retreatment interval data
• Launch timing, pricing, and physician training requirements

What's next?

The next concrete data point is the FDA approval letter and the updated prescribing information, which will set the regulatory floor for the new use. Once published, practices can begin formal patient-facing marketing of the neck indication and update consent documentation accordingly.

Industry watchers should also monitor the manufacturer's investor communications and quarterly results for any commentary on launch cadence, market sizing, and pipeline implications for the broader Juvéderm franchise.